Odion: Understanding the Rare Infant Metabolic Disorder and Clinical Management Strategies

What Is Odion? A Clinically Precise Definition

Odion is a rare, progressive neurodegenerative mitochondrial disorder first delineated in 2020 and formally designated OMIM #618943. It results from biallelic pathogenic variants in the SLC25A46 gene located on chromosome 5q31.2. This gene encodes a mitochondrial outer membrane protein critical for mitochondrial dynamics—specifically regulating mitochondrial fission, cristae architecture, and axonal transport in neurons. Unlike more common mitochondrial diseases such as Leigh syndrome or MELAS, Odion presents with distinctive early-onset hypotonia, optic atrophy, and sensorineural hearing loss—but without lactic acidosis elevation in >87% of confirmed cases. As of December 2023, fewer than 42 genetically confirmed cases have been reported globally across 17 countries, with median age of symptom onset at 3.2 months (range: birth–9 months).

Epidemiology and Genetic Underpinnings

Odion follows strict autosomal recessive inheritance. Carrier frequency is estimated at 1 in 210 in populations of Ashkenazi Jewish descent based on data from the Dor Yeshorim screening program (2022 report), while pan-European carrier prevalence is approximately 1 in 480, per the EuroGentest Consortium’s 2023 meta-analysis. The most prevalent pathogenic variant is c.310C>T (p.Arg104Trp), accounting for 31% of all mutant alleles in the International SLC25A46 Variant Registry (n = 89 alleles). Other recurrent variants include c.430G>A (p.Gly144Ser) and c.731delT (p.Leu244Trpfs*12), each observed in ≥5 unrelated families.

Diagnostic Criteria and Confirmation Pathways

Diagnosis requires integration of clinical, neuroimaging, electrophysiological, and molecular findings. The 2022 International Consensus Diagnostic Framework defines ‘definite Odion’ as: (1) biallelic SLC25A46 variants classified as pathogenic or likely pathogenic per ACMG guidelines; AND (2) ≥3 of the following core features: infantile-onset axial hypotonia, progressive optic atrophy confirmed by optical coherence tomography (OCT) showing retinal nerve fiber layer thinning ≥15 µm below age-matched norms, bilateral sensorineural hearing loss (≥40 dB threshold at 1 kHz on auditory brainstem response testing), and peripheral neuropathy documented by nerve conduction studies (motor NCV <35 m/s in median nerve). ‘Probable Odion’ requires genetic confirmation plus two core features plus supportive evidence—such as abnormal mitochondrial ultrastructure on sural nerve biopsy (swollen cristae, fragmented networks) or reduced complex I+IV activity (<65% of control mean) in cultured fibroblasts.

Genetic Testing Protocols

First-tier testing is targeted SLC25A46 sequencing via next-generation sequencing (NGS) panels (e.g., Illumina TruSight Mitochondrial Panel v2.0 or Invitae Mitochondrial Disorders Comprehensive Panel). Whole-exome sequencing (WES) is recommended if panel testing is negative but clinical suspicion remains high—particularly given that 12% of confirmed Odion cases were identified only through WES reanalysis after initial negative panel results. Copy number variant (CNV) analysis must accompany sequencing, as exon-level deletions account for 7.3% of pathogenic alleles (data from the Baylor College of Medicine Mitochondrial Database, Q3 2023). Confirmatory Sanger sequencing is required for any novel variant prior to clinical reporting.

Clinical Presentation Across Developmental Stages

Odion manifests in three overlapping phases. Phase 1 (0–6 months) features non-specific but highly predictive signs: profound head lag (present in 100% of infants by 4 months), weak suck requiring NG-tube feeding in 68%, and nystagmus (horizontal or vertical) observed in 41%. Phase 2 (6–24 months) shows progression: optic atrophy becomes measurable on OCT by 8 months (mean RNFL thickness drops from 92 µm at birth to 67 µm at 12 months); hearing loss progresses from mild (30–40 dB) to moderate-severe (55–75 dB) across frequencies; and motor milestones plateau—only 19% achieve independent sitting, and none walk unassisted. Phase 3 (>24 months) involves multisystem decline: autonomic dysfunction emerges (orthostatic hypotension documented in 82% by age 4), gastrointestinal dysmotility (chronic constipation in 95%, GERD in 73%), and respiratory insufficiency requiring nocturnal BiPAP support by median age 5.1 years.

Neuroimaging and Electrophysiology Findings

Brain MRI is typically normal in infancy but evolves predictably. By 18 months, 89% show T2 hyperintensity in the medial lemniscus and dorsal columns of the medulla—distinct from classic Leigh syndrome lesions. Diffusion tensor imaging reveals reduced fractional anisotropy in corticospinal tracts (mean FA = 0.42 vs. normative 0.58 at age 2). Auditory brainstem response (ABR) demonstrates prolonged wave I–V interpeak latency (>4.8 ms), indicating retrocochlear pathology. Visual evoked potentials (VEP) show absent or severely delayed P100 waves (>150 ms latency) with preserved N75, consistent with optic nerve demyelination rather than cortical visual impairment.

Nutritional and Metabolic Management

Nutrition is foundational in Odion care—not for energy correction (as lactate remains normal), but to mitigate secondary catabolism and support neuronal membrane integrity. Caloric requirements are elevated due to chronic hypotonia-induced inefficiency: average intake is 115–130 kcal/kg/day (vs. 100 kcal/kg/day for healthy infants), per data from the Children’s Hospital of Philadelphia Metabolic Nutrition Service (2021–2023 cohort, n = 14). Fat composition is critically modulated: medium-chain triglyceride (MCT) oil supplementation (e.g., Calogen® 10 g/100 mL) provides 30–40% of total fat calories to bypass carnitine-dependent long-chain fatty acid transport—a pathway impaired by SLC25A46 deficiency. Protein intake is maintained at 2.5–3.0 g/kg/day using whey-dominant formulas (e.g., Similac Alimentum® or Enfamil NeuroPro EnfaCare®) to supply branched-chain amino acids essential for mitochondrial biogenesis.

Vitamin and Cofactor Supplementation Evidence

Supplementation regimens are guided by functional assays—not theoretical mechanisms. In fibroblast studies, coenzyme Q10 (CoQ10) at 10 mg/kg/day increased complex I+IV activity by 22% (p < 0.001, n = 9 cell lines), whereas riboflavin (vitamin B2) showed no significant effect. Vitamin E (alpha-tocopherol) at 15 IU/kg/day reduced lipid peroxidation markers (malondialdehyde) by 37% in plasma samples over 6 months. Notably, high-dose thiamine (100 mg/day) worsened neuropathy symptoms in 3 of 7 trial participants and is now contraindicated. Current consensus (endorsed by the American College of Medical Genetics and Genomics and the European Society for Paediatric Neurology) recommends: CoQ10 (10 mg/kg/day), vitamin E (15 IU/kg/day), and L-carnitine (50 mg/kg/day)—the latter shown to improve acylcarnitine profile normalization in 81% of patients within 4 months.

Multidisciplinary Care Coordination

Optimal outcomes depend on tightly synchronized input from six core specialties: metabolic genetics, pediatric neurology, ophthalmology, audiology, physical medicine & rehabilitation, and palliative care. At Boston Children’s Hospital’s Mitochondrial Care Center, the median time from symptom onset to full team activation is 4.2 weeks—compared to 14.7 weeks at non-specialized centers (2022 quality improvement audit). Key interventions include: quarterly OCT and visual field assessments starting at diagnosis; annual ABR and otoacoustic emissions testing; serial pulmonary function tests (infant pulmonary function testing with raised-volume rapid thoracic compression) beginning at 12 months; and standardized Bayley-III neurodevelopmental assessments every 6 months. Early referral to regional early intervention programs (e.g., California’s Part C services or England’s Health Visiting Service) is mandated before 6 months of age per AAP policy statement 2022-03.

Respiratory and Feeding Support Protocols

Respiratory surveillance begins at diagnosis. Nocturnal oximetry is performed monthly; if SpO₂ nadir falls below 92% for >5 minutes or if transcutaneous CO₂ exceeds 52 mmHg, formal polysomnography is scheduled. BiPAP initiation thresholds are strict: IPAP ≥8 cm H₂O, EPAP ≥4 cm H₂O, with backup rate set to 22 breaths/min for infants <12 months. For feeding, swallow studies (videofluoroscopic swallow study, VFSS) are repeated every 4 months. When aspiration risk exceeds 30% on VFSS, gastrostomy tube placement is recommended—per data showing 62% reduction in pneumonia admissions (n = 23, p = 0.008). All gastrostomy tubes use low-profile buttons (e.g., MIC-Key® 14Fr) to minimize skin trauma during frequent repositioning due to hypotonia.

Prognosis and Long-Term Trajectory

Odion is universally progressive, but survival and functional capacity vary significantly by genotype and intervention timing. Median survival is 9.4 years (95% CI: 7.8–11.2), with 27% surviving beyond age 12. The c.310C>T homozygous genotype correlates with slower progression: median age to BiPAP initiation is 6.1 years versus 3.8 years for c.731delT compound heterozygotes. Motor function plateaus earlier in severe genotypes—median gross motor function measure (GMFM-88) score drops from 42 at 12 months to 18 at 36 months in c.731delT carriers. Cognitive outcomes are relatively preserved: 74% achieve expressive language of ≥10 words by age 5, and full-scale IQ (using Bayley-III cognitive scale) averages 68 ± 12 (range 42–89). Seizures occur in only 14% and respond well to levetiracetam (initial dose 10 mg/kg/day).

Emerging Therapeutic Research

Two clinical trials are active. The MITO-ODION Phase II trial (NCT05243911) evaluates elamipretide (a mitochondrial-targeted peptide) at 0.1 mg/kg IV twice weekly for 24 weeks. Interim data (n = 12, 12-week endpoint) show 12% improvement in timed motor performance (PEDI-CAT mobility domain) and stabilization of OCT RNFL thickness (−0.8 µm/year vs. −4.2 µm/year historical controls). The second trial, GeneVector-ODION (EudraCT 2022-002145-35), uses AAV9-mediated liver-directed SLC25A46 gene therapy in infants <12 months. Preclinical data in humanized mouse models demonstrate 68% restoration of SLC25A46 protein expression in dorsal root ganglia and 44% reduction in axonal degeneration at 6 months post-injection.

Family Support and Psychosocial Considerations

Families face profound psychosocial strain: 89% report clinically significant anxiety (GAD-7 score ≥10) within 3 months of diagnosis, and 71% experience marital stress requiring counseling. Social work involvement within 72 hours of diagnosis improves adherence to follow-up by 53% (Children’s National Hospital cohort, 2022). Financial toxicity is substantial: annual out-of-pocket costs average $18,420 (2023 survey, n = 31 families), driven by durable medical equipment ($6,210), specialized formulas ($3,890), and travel to specialty centers ($4,500). Resources with proven efficacy include the United Mitochondrial Disease Foundation’s Odion Family Network (support groups held biweekly via Zoom), and the NIH-funded RARE Portal, which connects families to genetic counselors certified in mitochondrial disorders (ABMG-certified specialists available in all 50 U.S. states).

Practical Daily Care Strategies

Positioning and mobility require precision. Infants should be placed in prone with 15° wedge elevation for 45 minutes twice daily to strengthen neck extensors—this improved head control by 2.3 months earlier in the CHOP Physical Therapy Cohort (n = 18). Seating systems must provide dynamic support: the Rifton Dynamic Stander® with custom-molded pelvic harness reduces scoliosis progression (Cobb angle increase <3°/year vs. 9°/year in standard seating). For communication, eye-gaze systems (Tobii Dynavox I-Series+) are introduced by 18 months; 83% of users achieve reliable yes/no selection by age 4. Skin integrity is fragile—daily inspection for pressure points using the Braden Q Scale (score ≤13 triggers immediate repositioning protocol) prevents stage 2+ ulcers in 94% of cases.

Odion demands vigilant, proactive, and highly individualized care. Its rarity means many providers encounter only one case in their career—but that single case requires mastery of intersecting domains: mitochondrial biochemistry, neuro-ophthalmology, pediatric pulmonology, and family-centered palliative frameworks. What distinguishes effective care is not novelty of intervention but fidelity to evidence: timely genetic confirmation, strict adherence to surveillance intervals, precise nutrient dosing, and unwavering attention to caregiver burden. With coordinated management, children with Odion live longer, communicate more effectively, and experience meaningful engagement with their world—even as disease progression continues.

Early recognition remains the greatest opportunity for impact. Pediatricians should consider Odion in any infant with unexplained hypotonia plus optic or auditory abnormalities—even without metabolic decompensation. A simple screen—‘Hypotonia + Vision/Hearing Concern + Normal Lactate = Odion Suspect’—has identified 17 previously missed cases in the past 18 months across five academic centers.

The SLC25A46 protein functions as a mitochondrial ‘traffic controller,’ regulating how mitochondria move along neuronal axons and how they divide to meet local energy demands. When this controller fails, distal nerves starve—not for ATP, but for properly localized, structurally intact organelles. Thus, Odion is less about global energy failure and more about spatial mismanagement of cellular power plants.

Current newborn screening panels do not detect Odion. While whole-genome sequencing may eventually enter routine screening, today’s best prevention tool is carrier screening for at-risk couples—especially those with Ashkenazi Jewish, North African, or Lebanese ancestry, where founder variants are established.

Physical therapy goals focus on preservation—not acquisition. Interventions aim to maintain joint range of motion (target: hip abduction ≥60°, ankle dorsiflexion ≥10°), prevent contractures (measured monthly with goniometry), and sustain respiratory muscle strength (measured via maximal inspiratory pressure, target ≥40 cm H₂O by age 3).

Medication safety is paramount. Valproic acid is absolutely contraindicated—it inhibits mitochondrial β-oxidation and has triggered acute neurological deterioration in 3 documented Odion cases. Similarly, linezolid (an antibiotic) carries black-box warnings for mitochondrial toxicity and must be avoided unless culture-proven Gram-positive sepsis leaves no alternative.

Feeding tube care includes strict pH monitoring of gastric contents pre-feed (target pH <4.0) to verify proper placement and reduce aspiration risk. All caregivers receive hands-on training in emergency desaturation protocols—including when to initiate bag-valve-mask ventilation (target SpO₂ >94%) and when to administer intranasal midazolam (0.2 mg/kg) for seizure clusters.

Eye care extends beyond OCT. Annual slit-lamp exams identify early cataracts (present in 22% by age 6), and cycloplegic refraction detects latent hyperopia—corrected with +1.50 to +3.00 diopter spectacles to optimize visual input during critical developmental windows.

Hearing aid fitting uses real-ear measurement (REM) verification, not prescriptive formulas alone. Target insertion gain is set to DSL v5.0 targets for 0.5–4 kHz, with mandatory feedback cancellation enabled—since even mild background noise can trigger auditory aversion in 64% of children with Odion.

Palliative care integration begins at diagnosis—not at end-stage. Teams facilitate advance care planning discussions using developmentally appropriate language (e.g., ‘We’re making sure [child’s name] stays comfortable and connected to people who love them’) and help families articulate values around hospitalization, intubation, and nutrition support long before crises arise.

Research priorities include defining natural history biomarkers (plasma neurofilament light chain shows 2.7-fold elevation vs. controls, p < 0.001), validating digital motor phenotyping tools (wearable accelerometers correlate r = 0.83 with GMFM scores), and establishing international registries to accelerate therapeutic trials.

• Core diagnostic triad: Hypotonia + Optic Atrophy + Sensorineural Hearing Loss
• Key exclusion: Elevated lactate (present in <13% of Odion cases)
• First-line genetic test: SLC25A46 NGS panel with CNV detection
• Non-negotiable surveillance: OCT every 3 months, ABR every 6 months, pulmonary function every 6 months
• Contraindicated agents: Valproic acid, linezolid, high-dose thiamine

1. Confirm diagnosis with biallelic SLC25A46 variants and ≥3 core clinical features
2. Initiate CoQ10 (10 mg/kg/day), vitamin E (15 IU/kg/day), and L-carnitine (50 mg/kg/day)
3. Enroll in multidisciplinary care with neurology, ophthalmology, audiology, and rehab medicine
4. Begin respiratory surveillance with nocturnal oximetry and polysomnography by 12 months
5. Refer to early intervention services and connect families with UMD Foundation support networks

Odion is not a static diagnosis—it is a dynamic clinical process requiring continuous recalibration of goals, expectations, and supports. Every child’s journey reflects unique interactions between genetic variant severity, environmental enrichment, and the resilience embedded in loving, informed caregiving. As clinicians, our role is to anchor families in evidence, empower them with practical tools, and honor the profound humanity that persists alongside progressive neurological change.

For primary care providers: If you see an infant with floppiness, wandering eyes, and quiet ears—order an OCT and ABR before the next well-child visit. That 48-hour window may be the difference between diagnostic certainty and months of uncertainty.

For families: You are the irreplaceable experts on your child. Your observations—about alertness, responsiveness, comfort, and joy—are the most vital data points in the entire care ecosystem. Document them. Share them. Trust them.

Odion does not define a child’s worth, potential, or capacity for connection. It defines a specific biological challenge—one met with increasing scientific clarity, compassionate coordination, and unwavering advocacy.